Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to diet and physical activity
Her public disclosure could be whats needed to destigmatize obesity, Northeastern University experts say, and encourage people who struggle with their weight to consider GLP-1 treatments
These hormones are GLP-1, Glucagon-Like Peptide-1, which binds to receptors in the brain and the pancreas to create the sensation of feeling full by slowing the digestive process, and GIP, Gastric Inhibitory Peptide, which works very similarly in the way it slows digestion but it binds to other receptors in the brain but help the body create insulin resulting in a decrease in food cravings and appetite
If you need help, please contact us!
Discontinuing tirzepatide may affect any reductions in AHI and improvements in OSA severity experienced while on the drug
That said, if the nausea lingers or starts to disrupt your daily routine, its something that shouldnt be ignored